J
Joseph M. Herman
Researcher at Johns Hopkins University School of Medicine
Publications - 291
Citations - 17120
Joseph M. Herman is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Pancreatic cancer & Cancer. The author has an hindex of 64, co-authored 266 publications receiving 14557 citations. Previous affiliations of Joseph M. Herman include University of Texas MD Anderson Cancer Center & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue,Baojin Fu,Shinichi Yachida,Mingde Luo,Hisashi Abe,Clark M. Henderson,Felip Vilardell,Zheng Wang,Jesse Keller,Priya Banerjee,Joseph M. Herman,John L. Cameron,Charles J. Yeo,Marc K. Halushka,James R. Eshleman,Marian Raben,Alison P. Klein,Ralph H. Hruban,Manuel Hidalgo,Daniel A. Laheru +19 more
TL;DR: Pancreatic cancers are represented by distinct genetic subtypes with significantly different patterns of failure, and determinations of DPC4 status at initial diagnosis may be of value in stratifying patients into treatment regimens related to local control versus systemic therapy.
Journal ArticleDOI
Recent Progress in Pancreatic Cancer
Christopher L. Wolfgang,Joseph M. Herman,Daniel A. Laheru,Alison P. Klein,Michael A. Erdek,Elliot K. Fishman,Ralph H. Hruban +6 more
TL;DR: In this paper, it is shown that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer, and it is clear that multi-disciplinary care is the best way to care for patients.
Journal ArticleDOI
Impact of Sarcopenia on Outcomes Following Resection of Pancreatic Adenocarcinoma
Peter D. Peng,Omar Hyder,Amin Firoozmand,Peter J. Kneuertz,Richard D. Schulick,Donghang Huang,Martin A. Makary,Kenzo Hirose,Barish H. Edil,Michael A. Choti,Joseph M. Herman,John L. Cameron,Christopher L. Wolfgang,Timothy M. Pawlik +13 more
TL;DR: Sarcopenia was an objective measure of patient frailty that was strongly associated with long-term outcome independent of tumor-specific factors, and was a predictor of survival following pancreatic surgery.
Journal ArticleDOI
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma
Joseph M. Herman,Daniel T. Chang,Karyn A. Goodman,Avani S. Dholakia,Siva P. Raman,Amy Hacker-Prietz,Christine A. Iacobuzio-Donahue,Mary E. Griffith,Timothy M. Pawlik,Jonathan S. Pai,Eileen M. O'Reilly,George A. Fisher,Aaron T. Wild,Lauren M. Rosati,Lei Zheng,Christopher L. Wolfgang,Daniel A. Laheru,Laurie Ann Columbo,Elizabeth A. Sugar,Albert C. Koong +19 more
TL;DR: This phase 2 multi‐institutional study was designed to determine whether gemcitabine with fractionated stereotactic body radiotherapy (SBRT) results in acceptable late grade 2 to 4 gastrointestinal toxicity when compared with a prior trial of GEM with single‐fraction SBRT in patients with locally advanced pancreatic cancer (LAPC).
Journal ArticleDOI
Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
Hiroshi Haeno,Mithat Gonen,Meghan B. Davis,Joseph M. Herman,Christine A. Iacobuzio-Donahue,Franziska Michor +5 more
TL;DR: The effects of different treatment modalities are analyzed, finding that therapies that efficiently reduce the growth rate of cells earlier in the course of treatment appear to be superior to upfront tumor resection.